Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 13/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 4/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343813 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL6352686 | 0.82 | HTR1A (1.00) | DRD2DRD3HTR1A | |
| SCHEMBL9127222 | 0.77 | DRD2 (0.63) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL7376178 | 0.77 | DRD2 (0.62) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL6483129 | 0.77 | DRD2 (1.00) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7343645 | 0.76 | DRD2 (0.61) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL7353199 | 0.75 | HTR1A (0.72) | DRD2DRD3HTR1A | |
| SCHEMBL7348730 | 0.73 | DRD2 (0.58) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL7348495 | 0.73 | DRD2 (0.58) | DRD2DRD3HTR1APARP1 | |
| SCHEMBL23261784 | 0.73 | HTR1A (0.68) | DRD2DRD3HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138200-A1 | Pharmaceutical compositions for treatment of Parkinson's disease | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | claimed |
| US-20100069397-A1 | SEXUAL DYSFUNCTION COMPOUNDS | PHARMACIA AB | 2010-03-18 | — | — | US | disclosed |
| US-20070092554-A1 | Sexual Dysfunction Compounds | PHARMACIA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1471890-B1 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORP (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1545521-A2 | COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTION | Pharmacia Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050043296-A1 | Compositions and methods for treating sexual dysfunction | PHARMACLA & UPJOHN COMPANY | 2005-02-24 | — | — | US | disclosed |
| US-20040138200-A1 | Pharmaceutical compositions for treatment of Parkinson's disease | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-20040126448-A1 | Sexual dysfunction compounds | MCNEIL AB (FORMERLY KNOWN AS PFIZER CONSUMER HEALTHCARE HEALTH AB) (SE) | 2004-07-01 | — | — | US | disclosed |
| WO-2004032853-A2 | COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTION | PHARMACIA CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | disclosed |
| US-20030022912-A1 | Rapid-onset medicament for treatment of sexual dysfunction | PHARMACIA & UPJOHN COMPANY | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069397-A1 | SEXUAL DYSFUNCTION COMPOUNDS | PDE3B, PDE3A, PDE5A | DRD2 171/4885DRD3 221/4885HTR1A 61/4885 |
| US-20040126448-A1 | Sexual dysfunction compounds | PDE3B, PDE3A, PDE5A | DRD2 171/4885DRD3 221/4885HTR1A 61/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | DRD2 1971/4885DRD3 1736/4885HTR1A 768/4885 |
| US-20040138200-A1 | Pharmaceutical compositions for treatment of Parkinson's disease | PARK7, SNCA, OTC | DRD2 2144/4885DRD3 2717/4885HTR1A 1634/4885 |
| US-20030022912-A1 | Rapid-onset medicament for treatment of sexual dysfunction | SHBG, PDE3A, PDE3B | DRD2 308/4885DRD3 453/4885HTR1A 148/4885 |
| US-20070092554-A1 | Sexual Dysfunction Compounds | PDE3B, PDE3A, PDE5A | DRD2 171/4885DRD3 221/4885HTR1A 61/4885 |
| US-20050043296-A1 | Compositions and methods for treating sexual dysfunction | SORD, SHBG, SLC5A1 | DRD2 1185/4885DRD3 1245/4885HTR1A 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.